Busca un médico

Stacy D. D'Andre, M.D.

  1. Oncologist

Publicaciones

  1. Hurtado MD, Tama E, D'Andre S, Shufelt CL. The relation between excess adiposity and breast cancer in women: Clinical implications and management. Crit Rev Oncol Hematol. 2024 Jan; 193:104213 Epub 2023 Nov 24
    View PubMed
  2. Cathcart-Rake EJ, Tevaarwerk AJ, Haddad TC, D'Andre SD, Ruddy KJ. Advances in the care of breast cancer survivors. BMJ. 2023 Sep 18; 382:e071565 Epub 2023 Sept 18
    View PubMed
  3. Marell PS, Vierkant RA, Olson JE, Herrmann J, Larson NL, Lebrasseur NK, D'Andre SD, Ehlers DK, Stan DL, Cheville AL, Barksdale T, Loprinzi CL, Couch FJ, Ruddy KJ. Changes in amount and intensity of physical activity over time in breast cancer survivors. JNCI Cancer Spectr. 2023 Aug 31; 7 (5)
    View PubMed
  4. D'Andre SD, Bauer BA, Hofmann MB, Burckhard JL, Montane HN, Loprinzi CL. Dietary supplement use and recommendations for discontinuation in an integrative oncology clinic. Support Care Cancer. 2022 Dec 16; 31 (1):40
    View PubMed
  5. Liau LM, Ashkan K, Brem S, Campian JL, Trusheim JE, Iwamoto FM, Tran DD, Ansstas G, Cobbs CS, Heth JA, Salacz ME, D'Andre S, Aiken RD, Moshel YA, Nam JY, Pillainayagam CP, Wagner SA, Walter KA, Chaudary R, Goldlust SA, Lee IY, Bota DA, Elinzano H, Grewal J, Lillehei K, Mikkelsen T, Walbert T, Abram S, Brenner AJ, Ewend MG, Khagi S, Lovick DS, Portnow J, Kim L, Loudon WG, Martinez NL, Thompson RC, Avigan DE, Fink KL, Geoffroy FJ, Giglio P, Gligich O, Krex D, Lindhorst SM, Lutzky J, Meisel HJ, Nadji-Ohl M, Sanchin L, Sloan A, Taylor LP, Wu JK, Dunbar EM, Etame AB, Kesari S, Mathieu D, Piccioni DE, Baskin DS, Lacroix M, May SA, New PZ, Pluard TJ, Toms SA, Tse V, Peak S, Villano JL, Battiste JD, Mulholland PJ, Pearlman ML, Petrecca K, Schulder M, Prins RM, Boynton AL, Bosch ML. Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial. JAMA Oncol. 2022 Nov 17 [Epub ahead of print]
    View PubMed
  6. Marell PS, Vierkant RA, Olson JE, Herrmann J, Larson N, LeBrasseur NK, D'Andre SD, Cheville AL, Barksdale T, Loprinzi CL, Couch F, Ruddy KJ. Factors Associated With Physical Activity Levels in Patients With Breast Cancer. Oncologist. 2022 Oct 1; 27 (10):e811-e814
    View PubMed
  7. Gupta R, Meric-Bernstam F, Rothe M, Garrett-Mayer E, Mangat PK, D'Andre S, Ahn ER, O'Lone R, Halabi S, Grantham GN, Schilsky RL. Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study. JCO Precis Oncol. 2022 Oct; 6:e2200306
    View PubMed
  8. Liu JF, Brady MF, Matulonis UA, Miller A, Kohn EC, Swisher EM, Cella D, Tew WP, Cloven NG, Muller CY, Bender DP, Moore RG, Michelin DP, Waggoner SE, Geller MA, Fujiwara K, D'Andre SD, Carney M, Alvarez Secord A, Moxley KM, Bookman MA. Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial. J Clin Oncol. 2022 Jul 01; 40(19):2138-2147. Epub 2022 Mar 15.
    View PubMed
  9. E Swisher, A Miller, E Kohn, M Brady, M Radke, C Pennil, N Khasnavis, J Buscema, W Tew, C Muller, E Hill, R Moore, D Michelin, S Waggoner, M Geller, K Fujiwara, S D'Andre, J Liu, MJ Birrer. LBA34 Association of homologous recombination deficiency (HRD) with clinical outcomes in a phase III study of olaparib or cediranib and olaparib compared to platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer (PSOC): Biomarker analyses from NRG-GY004 Annals of Oncology. 2021; 32:S1309.
  10. Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmana J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, McFadden E, Karantza V, Lakhani SR, Yothers G, Campbell C, Geyer CE Jr, OlympiA Clinical Trial Steering Committee and Investigators. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. N Engl J Med. 2021 Jun 24; 384 (25):2394-2405 Epub 2021 June 03
    View PubMed
  11. Evan P Pisick, Michael Rothe, Pam K Mangat, Liz Garrett-Mayer, Francis P Worden, Jessica R Bauman, Siqing Fu, Rom S Leidner, Ani Sarkis Balmanoukian, Carmen Calfa, Daniel R Carrizosa, Stacy D D'Andre, Lisle Nabell, Min S Park, Steven Francis Powell, Ramya Thota, Richard L Schilsky. Palbociclib (P) in patients (pts) with head and neck cancer (HNC) with CDKN2A loss or mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study Journal of Clinical Oncology. 2021; 39(15_suppl):6043-6043. Epub 2021 May 28.
  12. D'Andre S, McAllister S, Nagi J, Giridhar KV, Ruiz-Macias E, Loprinzi C. Topical Cannabinoids for Treating Chemotherapy-Induced Neuropathy: A Case Series. Integr Cancer Ther. 2021 Jan-Dec; 20:15347354211061739
    View PubMed
  13. Joyce F Liu, Mark F Brady, Ursula A Matulonis, Austin Miller, Elise C Kohn, Elizabeth M Swisher, William P Tew, Noelle Gillette Cloven, Carolyn Muller, David Bender, Richard G Moore, David Paul Michelin, Steven E Waggoner, Melissa Ann Geller, Keiichi Fujiwara, Stacy D D'Andre, Michael Carney, Angeles Alvarez Secord, Katherine M Moxley, Michael A Bookman. A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer Journal of Clinical Oncology. 2020; 38(15_suppl):6003. Epub 2020 May 25.
  14. Vergote I, Scambia G, O'Malley DM, Van Calster B, Park SY, Del Campo JM, Meier W, Bamias A, Colombo N, Wenham RM, Covens A, Marth C, Raza Mirza M, Kroep JR, Ma H, Pickett CA, Monk BJ, TRINOVA-3/ENGOT-ov2/GOG-3001 investigators. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019 Jun; 20 (6):862-876 Epub 2019 May 07
    View PubMed
  15. Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, Iwamoto FM, Dropcho EJ, Moshel YA, Walter KA, Pillainayagam CP, Aiken R, Chaudhary R, Goldlust SA, Bota DA, Duic P, Grewal J, Elinzano H, Toms SA, Lillehei KO, Mikkelsen T, Walbert T, Abram SR, Brenner AJ, Brem S, Ewend MG, Khagi S, Portnow J, Kim LJ, Loudon WG, Thompson RC, Avigan DE, Fink KL, Geoffroy FJ, Lindhorst S, Lutzky J, Sloan AE, Schackert G, Krex D, Meisel HJ, Wu J, Davis RP, Duma C, Etame AB, Mathieu D, Kesari S, Piccioni D, Westphal M, Baskin DS, New PZ, Lacroix M, May SA, Pluard TJ, Tse V, Green RM, Villano JL, Pearlman M, Petrecca K, Schulder M, Taylor LP, Maida AE, Prins RM, Cloughesy TF, Mulholland P, Bosch ML. Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med. 2018 Jun 29; 16 (1):179 Epub 2018 June 29
    View PubMed
  16. Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, Iwamoto FM, Dropcho EJ, Moshel YA, Walter KA, Pillainayagam CP, Aiken R, Chaudhary R, Goldlust SA, Bota DA, Duic P, Grewal J, Elinzano H, Toms SA, Lillehei KO, Mikkelsen T, Walbert T, Abram SR, Brenner AJ, Brem S, Ewend MG, Khagi S, Portnow J, Kim LJ, Loudon WG, Thompson RC, Avigan DE, Fink KL, Geoffroy FJ, Lindhorst S, Lutzky J, Sloan AE, Schackert G, Krex D, Meisel HJ, Wu J, Davis RP, Duma C, Etame AB, Mathieu D, Kesari S, Piccioni D, Westphal M, Baskin DS, New PZ, Lacroix M, May SA, Pluard TJ, Tse V, Green RM, Villano JL, Pearlman M, Petrecca K, Schulder M, Taylor LP, Maida AE, Prins RM, Cloughesy TF, Mulholland P, Bosch ML. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med. 2018 May 29; 16 (1):142
    View PubMed
  17. Martinez-Bosch N, Fernandez-Barrena MG, Moreno M, Ortiz-Zapater E, Munne-Collado J, Iglesias M, Andre S, Gabius HJ, Hwang RF, Poirier F, Navas C, Guerra C, Fernandez-Zapico ME, Navarro P. Galectin-1 drives pancreatic carcinogenesis through stroma remodeling and Hedgehog signaling activation. Cancer Res. 2014 Jul 1; 74 (13):3512-24 Epub 2014 May 08
    View PubMed
  18. D'Andre S, Sargent DJ, Cha SS, Buroker TR, Kugler JW, Goldberg RM, O'Connell MJ, Poon MA. 5-Fluorouracil-based chemotherapy for advanced colorectal cancer in elderly patients: a north central cancer treatment group study. Clin Colorectal Cancer. 2005 Jan; 4(5):325-31.
    View PubMed
  19. Jacobson SD, Hartmann LH. Cancer treatment issues in older women Principles of Gender Specific Medicine. 2004.
  20. Jacobson SD, Loprinzi CL, Sloan JA, Wilke JL, Novotny PJ, Okuno SH, Jatoi A, Moynihan TJ. Glutamine does not prevent paclitaxel-associated myalgias and arthralgias. J Support Oncol. 2003 Nov-Dec; 1(4):274-8.
    View PubMed
  21. Sargent DJ, Goldberg RM, Jacobson SD, Macdonald JS, Labianca R, Haller DG, Shepherd LE, Seitz JF, Francini G. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001 Oct 11; 345 (15):1091-7
    View PubMed
  22. Jacobson SD, Alberts SR, O'Connell MJ. Pancreatic cancer in the older patient. Oncology (Williston Park). 2001 Jul; 15 (7):926-32; discussion 935-7
    View PubMed
  23. Sargent D, Goldberg R, Jacobson S, Macdonald J, Labianca R, Haller D, Shepherd L, Seitz J, Francini G. Adjuvant chemotherapy for colon cancer in elderly patients: A pooled analysis of 3351 patients N Engl J Med. 2001; 345:1091-1097.
  24. Wandzilak TR, D'Andre SD, Davis PA, Willimas HE. Effect of high dose vitamin C on urinary oxalate. J Urol. 1994 Apr; 151(4):834-7.
    View PubMed
  25. Wandzilak TR, Calo L, D'Andre SD, Borsatti A, William HE. Oxalate transport in cultrured porcine renal epithelial cells. Urol Res. 1992; 20(5):341-5.
    View PubMed
PST-20529673